Datapoint: Roche Scores Expanded SMA Nod for Evrysdi

The FDA this week approved Roche’s at-home spinal muscular atrophy (SMA) therapy Evrysdi in children under two months old. The treatment was first approved for SMA in adults and older children in August 2020. It currently holds covered or better status for 81% of all insured lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 6/1/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 8

Datapoint: Humana to Shutter SeniorBridge

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 7

Datapoint: Rigel’s New AML Drug Will Face Off Against Tibsovo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: United Projects 9% MA Growth in 2023

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today